AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

FTRE · NASDAQ · Biotechnology

Fortrea (FTRE)

Runs clinical trials and development services for drug, biotech, and device sponsors.

$20.19

vs last close−0.24 (−1.17%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	714	775	662	662	675	697	651	710	701	661	637	678
Cost of revenue	564	656	554	525	527	556	535	596	598	549	533	539
Gross profit	150	120	108	137	148	141	117	114	103	112	104	139
	140	130	145	188	166	197	637	125	119	103	101	124
	107	99	120	156	136	148	122	125	107	103	101	102
General & administrative	0	0	0	0	0	0	0	0	0	0	0	102
Other expenses	33	32	25	32	30	48	515	0	12	0	0	22
Operating income	10	−11	−37	−51	−18	−56	−520	−11	−16	9	3	15
	−32	−30	−38	−38	−18	−19	−28	−360	−13	−44	−16	−16
Interest expense	35	35	34	45	22	22	22	23	23	23	19	19
Other non-operating income	−2	−4	4	−8	−5	−3	6	337	−10	21	−3	0
Income before tax	−22	−41	−76	−89	−36	−75	−548	−371	−29	−36	−12	−1
Income tax expense	−6	−5	4	11	−17	−1	15	4	−13	−3	11	12
Net income from continuing operations	−16	−36	−80	−99	−19	−74	−563	−375	−16	−33	−24	−13
Discontinued operations	2	0	−21	−39	−9	13	0	0	0	0	0	0
Net income	−14	−36	−101	−138	−28	−61	−563	−375	−16	−33	−24	−13
EPS, basic	−$0.15	−$0.41	−$1.15	−$1.55	−$0.31	−$0.68	−$6.30	−$4.14	−$0.17	−$0.36	−$0.26	−$0.14
EPS, diluted	−$0.15	−$0.41	−$1.15	−$1.55	−$0.31	−$0.68	−$6.30	−$4.14	−$0.17	−$0.36	−$0.26	−$0.14
Weighted average shares, basic	87	88	89	89	90	90	89	91	91	91	91	94
Weighted average shares, diluted	87	88	89	89	90	90	89	91	91	91	91	94
EBITDA	38	17	−18	−22	8	−32	−506	−328	14	7	26	34
Depreciation & amortization	25	24	24	21	21	21	20	20	20	19	20	20
EBIT	13	−7	−41	−43	−13	−53	−526	−348	−6	−12	7	15